Professional Documents
Culture Documents
Introduction: What Is Hiv and Aids?
Introduction: What Is Hiv and Aids?
Human immune-deficiency virus (HIV) is a virus that attacks the human immune system. In the
process of reproducing itself, it destroys the body’s natural ability to fight off disease and other
infections. HIV causes people to be more vulnerable to disease. HIV leads to Acquired Immune
Deficiency Syndrome (AIDs). Due to weakened immune system, people infected with AIDs die from
peripheral illness such as malaria, tuberculosis, or various STDs which would otherwise be treatable
in no-HIV positive people.
Causes of AIDs
AIDS is a sexually transmitted disease caused by HIV at its
advanced stage of infection. At this point much of the body’s
immune system is damaged, making the HIV infected person more
vulnerable to infectious diseases.
Transmission
HIV is transmitted in blood, semen, vaginal fluids, and breast milk. The most common ways HIV is
spread are by:
A pregnant woman who is HIV positive can also infect her baby with the virus.
In a pregnant woman who has HIV, the virus is transmitted to the baby during exchange of
substances between maternal blood and fetus.
HIV is also transmitted to the baby form the mother during breastfeeding.
HIV is not transmitted by simple casual contact such as kissing, sharing drinking glasses, or hugging.
Some people develop HIV symptoms shortly after being infected. But it usually takes more than 10
years. There are several stages of HIV disease. The first HIV symptoms may include swollen glands
in the throat, armpit, or groin. Other early HIV symptoms include slight fever, headaches, fatigue,
and muscle aches. These symptoms may last for only a few weeks. Then there are usually no HIV
symptoms for many years. That is why it can be hard to know if a person has HIV, and so to
determine if a person has HIV medical tests are important.
AIDS symptoms appear much later than HIV symptoms. In addition to a badly damaged immune
system, a person with AIDS may also have:
thrush — a thick, whitish coating of the tongue or mouth that is caused by a yeast infection
and sometimes accompanied by a sore throat
chronic pelvic inflammatory disease
severe and frequent infections
periods of extreme and unexplained tiredness that may be combined with headaches,
lightheadedness, and/or dizziness
bruising more easily than normal
long periods of frequent diarrhea
frequent fevers and night sweats
swelling or hardening of glands located in
the throat, armpit, or groin
periods of persistent, deep, dry coughing
increasing shortness of breath
the appearance of discolored or purplish
growths on the skin or inside the mouth
unexplained bleeding from growths on the
skin, from the mouth, nose, anus, vagina, or from
any opening in the body
frequent or unusual skin rashes
severe numbness or pain in the hands or
feet, the loss of muscle control and reflex,
paralysis, or loss of muscular strength
Confusion, personality change, or decreased mental abilities.
The lower a person’s CD4+ T-cell count goes, the more susceptible the person is to viruses and
infections that an otherwise healthy body could fight. In the initial stages of the infection, the
decline in T-cell count is gradual. The first few months and years after a person is infected, T-cell
counts may remain very near normal or only slightly decreased. It’s when T-cell numbers begin to
decrease at a greater rate that patients with HIV begin noticing additional, worsening symptoms of
the infection.
An HIV infection is typically divided into four stages: acute primary infection, clinical latent
infection, symptomatic HIV infection, and progression from HIV to AIDS.
Entry Inhibitors
Entry inhibitors work by preventing HIV from entering healthy CD4 cells (T-cells) in the body.
They work by attaching themselves to proteins on the surface of CD4 cells or proteins on the
surface of HIV. In order for HIV to bind to CD4 cells, the proteins on HIV's outer coat must bind to
the proteins on the surface of CD4 cells. Entry inhibitors prevent this from happening. Some entry
inhibitors target the gp120 or gp41 proteins on HIV's surface. Some entry inhibitors target the CD4
protein or the CCR5 or CXCR4 receptors on a CD4 cell's surface. If entry inhibitors are successful
in blocking these proteins, HIV is unable to bind to the surface of CD4 cells and gain entry into the
cells.
When HIV infects a CD4 cell in a person's body, it copies its own genetic code into the cell's DNA.
In this way, the cell is then "programmed" to create new copies of HIV. HIV's genetic material is in
the form of RNA. In order for it to infect CD4 cells, it must first convert its RNA into DNA. HIV's
reverse transcriptase enzyme is needed to perform this process.
NNRTIs, also known as "non-nucleosides" or "non-nukes" for short, attach themselves to reverse
transcriptase and prevent the enzyme from converting RNA to DNA. In turn, HIV's genetic material
cannot be incorporated into the healthy genetic material of the cell, and prevents the cell from
producing new virus.
NRTIs, sometimes called "nucleoside analogues" or "nukes," contain faulty versions of the building
blocks (nucleotides) used by reverse transcriptase to convert RNA to DNA. When reverse
transcriptase uses these faulty building blocks, the new DNA cannot be built correctly. In turn,
HIV's genetic material cannot be incorporated into the healthy genetic material of the cell and
prevents the cell from producing new virus.
Integrase Inhibitors
In order for HIV to successfully take over a CD4 cell's machinery so that it can produce new
viruses, HIV's RNA is converted into DNA by the reverse transcriptase enzyme
(nucleotide/nucleoside reverse transcriptase inhibitors can block this process). After the "reverse
transcription" of RNA into DNA is complete, HIV's DNA must then be incorporated into the CD4
cell's DNA. This is known as integration. As their name implies, integrase inhibitors work by
blocking this process.
When HIV infects a CD4 cell in a person's body, it copies its own genetic code into the cell's DNA.
The CD4 cell is then "programmed" to make new HIV genetic material and HIV proteins. The
proteins must be cut up by the HIV protease—a protein-cutting enzyme—to make functional new
HIV particles. PIs block the protease enzyme and prevent the cell from producing new viruses.
Prevention of AIDS
These processes are quite effective in preventing the spread of HIV, thus decreasing the chances
and number of people being infected by the virus and being safe from AIDS as a result.